GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cogstate Ltd (OTCPK:COGZF) » Definitions » Forward PE Ratio

Cogstate (Cogstate) Forward PE Ratio : 36.16 (As of May. 03, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Cogstate Forward PE Ratio?

Cogstate's Forward PE Ratio for today is 36.16.

Cogstate's PE Ratio without NRI for today is 28.13.

Cogstate's PE Ratio for today is 28.13.


Cogstate Forward PE Ratio Historical Data

The historical data trend for Cogstate's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cogstate Forward PE Ratio Chart

Cogstate Annual Data
Trend 2022-12 2023-10 2024-04
Forward PE Ratio
31.85 31.75 35.34

Cogstate Semi-Annual Data
2022-03 2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2024-03
Forward PE Ratio 3.22 16.23 32.47 31.85 22.47 25.25 33.90 32.79

Competitive Comparison of Cogstate's Forward PE Ratio

For the Health Information Services subindustry, Cogstate's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cogstate's Forward PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Cogstate's Forward PE Ratio falls into.



Cogstate Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Cogstate  (OTCPK:COGZF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Cogstate Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Cogstate's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cogstate (Cogstate) Business Description

Traded in Other Exchanges
Address
161 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the company is the sale of technology and services for the measurement of cognition, where services include scientific consultancy, project management, data management, statistical analysis, and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.